UMIN ID: C000000348
Registered date:10/03/2006
Prevention of VZV reactivation using long-term low-dose valacyclovir after allogeneic hematopoietic stem cell transplantation.
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | allogeneic hematopoietic stem cell transplantation recipients |
| Date of first enrollment | 2002/05/01 |
| Target sample size | 40 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Start valacyclovir at 500mg/day thrice weekly from day 36 after transplantation. |
Outcome(s)
| Primary Outcome | Incidence of VZV reactivation within 2 years after transplantation. |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 16years-old |
|---|---|
| Age maximum | 70years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Patients with hematological malignancies not in remission. Severe organ dysfunction |
Related Information
| Primary Sponsor | Japan Hematology & Oncology Clinical Study Group (J-HOCS) |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Japan Hematology & Oncology Clinical Study Group (J-HOCS) |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Yoshinobu Kanda |
| Address | 7-3-1 Hongo, Bunkyo, Tokyo, Japan Japan |
| Telephone | 03-3815-5411 |
| ycanda-tky@umin.ac.jp | |
| Affiliation | University of Tokyo Hospital Department of Hematology & Oncology |
| scientific contact | |
| Name | Yoshinobu Kanda |
| Address | 7-3-1 Hongo, Bunkyo, Tokyo, Japan Japan |
| Telephone | 03-3815-5411 |
| Affiliation | University of Tokyo Hospital Department of Hematology & Oncology |